Hemanext has committed its resources to the continuing effort of the transfusion medicine community to save lives and improve patient outcomes. The company is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy.
View Investor Portal for confidential information and updates. Learn about Hemanext ONE technology.
New Investor? CLICK HERE to sign-up.
Research shows that hypoxic storage preserves faster oxygen unloading from red blood cells...
LEXINGTON, Mass., July 12, 2022 - PR NEWSWIRE – Hemanext Inc., a leading innovator in blood...
Hemanext Announces Appointment of Daan Kok as the Executive Vice President & General Manager of Hemanext for Europe, Middle East, and Africa
LEXINGTON, Mass., July 05, 2022 - (PR.com) – Hemanext Inc. (“Hemanext” or the “Company”), a...
LEXINGTON, Mass., February 02, 2022, PR NEWSWIRE – Hemanext Inc. (“Hemanext” or the “Company”), a...
Hot Topics in Transfusion Medicine
Research showing promise and opportunity for innovations in blood quality in the field of transfusion medicine.
Impact of the Age of Blood
Bruun-Rasmussen P, et al. Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data. Blood. 2022; doi: 10.1182/blood.2022015892.
A study at the University of Copenhagen investigated the adverse effects of the storage of red blood cell (RBC) units. This study was conducted using real-world data from a Danish blood transfusion database from 2008-2018, marginal structural models (MSM) to estimate the potential causal effect of transfusing RBC units with different storage durations, and a unique directed acyclic graph (DAG) of study assumptions used to suggest and adjust covariates for subsequent statistical modeling adjustment.
- Enrollment: 89,799 patients received more than 340,000 RBC transfusions met the eligibility criteria (chronic and massive transfusion recipients were excluded)
- Endpoints: An individual receiving >1-week old blood has a 2.44% higher chance of dying during a 28-day follow-up period than someone receiving < 1-week old blood and a 2.29% higher chance of dying or having a thromboembolic event during a 28-day follow-up period than someone receiving < 1-week old blood
This study suggests that transfusing exclusively older RBC units stored for >1 or 2 weeks increases the 28-day recipient mortality and risk of thromboembolism or death compared with transfusing fresher RBC units.
Curated resources for news, contact information, and newsletter sign-up.